Related Experiment Video
Updated: Sep 6, 2025
06:53
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
8.8K
Detection of IDH1 Mutations in Plasma Using BEAMing Technology in Patients with Gliomas
Santiago Cabezas-Camarero1, Vanesa García-Barberán2, Rebeca Pérez-Alfayate3
1Head & Neck Cancer, Neuro-Oncology and Genetic Counseling Unit, Medical Oncology Department, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico Universitario San Carlos, Paseo del Profesor Martín Lagos S/N, 28040 Madrid, Spain.
Cancers
|June 24, 2022
Summary
Liquid biopsy using circulating tumor DNA (ctDNA) shows promise for glioma molecular testing. BEAMing detected IDH1 mutations in plasma with high specificity but modest sensitivity in this glioma study.
Area of Science:
- Neuro-oncology
- Molecular Diagnostics
- Genetics
Background:
- Molecular testing in glioma patients, particularly using blood-based liquid biopsy, remains under-investigated.
- Isocitrate dehydrogenase 1 (IDH1) mutations are key biomarkers in glioma classification and prognosis.
- Circulating tumor DNA (ctDNA) in peripheral blood (PB) offers a non-invasive method for molecular monitoring.
Purpose of the Study:
- To investigate the utility of blood-based liquid biopsy for molecular testing in glioma patients.
- To correlate IDH1 mutation detection in plasma ctDNA with primary tumor mutations using next-generation sequencing (NGS) and BEAMing technology.
- To assess the clinical sensitivity and specificity of plasma IDH1 mutation detection in gliomas.
Main Methods:
- Prospective single-center study enrolling 10 patients with Grade II-IV gliomas.
- Peripheral blood (PB) collection at various timepoints for ctDNA analysis.
- Next-generation sequencing (NGS) for IDH1 mutation analysis in tumor tissue.
- Beads, Emulsion, Amplification and Magnetics (BEAMing) for IDH1 mutation detection in plasma ctDNA.
Main Results:
- IDH1 mutations were detected in plasma ctDNA in 3 out of 6 (50%) IDH1-mutant gliomas.
- Plasma IDH1 mutation detection occurred at diagnosis or during disease progression.
- BEAMing demonstrated 100% clinical specificity for IDH1 mutations in plasma, with no false positives in wild-type cases. Clinical sensitivity was modest, with a high false-negative rate (86%).
Conclusions:
- BEAMing technology can detect IDH1 mutations in plasma ctDNA of glioma patients, showing high specificity.
- The modest sensitivity suggests limitations for early detection or monitoring in all cases.
- Larger prospective studies are warranted to further explore ctDNA dynamics and its response to therapy in IDH1-mutant gliomas.
